Very attractive and massive undervalued Biotech Stock with many Major News on the way . Axsome has 4 Phase 3 clinical trials ongoing in various indication targeting very large Markets .This Stock is brutally undervalued with Market cap of $83 million and $50 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) over 50% of O/S is owned by Insider and Institutions which is a good sign . This undiscovered goldmine could be the next 10 bagger gem if just oneof their 4 Phase 3 program is successful .GL Axsome (AXSM) Market-Cap: $83 Million Cash: $50.6 Million Price:$3.60 Shares Out: 23 Million Anticipated Near-Term Clinical Milestones Clinical Trial Initiations: -- Phase 2/3 clinical trial of AXS-05 in AD agitation (2Q 2017) Clinical Trial Readouts: -- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (3Q 2017) -- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017) -- Phase 3 STRIDE-1 trial of AXS-05 in TRD, top-line data (1Q 2018) New Presentation http://redirect.viglink.com/?key=bb...25/254022/Axsome_Presentation_14_Mar_2017.pdf Major Shareholders Herriott Tabuteau, MD 7 351 729 38,4% Fidelity Management & Research Co. 2 361 625 12,3% JPMorgan Asset Management (UK) Ltd. 1 432 456 7,48% Mark Coleman, MD 647 998 3,38% BlackRock Fund Advisors 426 837 2,23% Stifel Trust Co., NA 415 279 2,17% The Vanguard Group, Inc. 272 189 1,42% Lombard Odier Asset Management (USA) Corp. 250 000 1,31% JPMorgan Investment Management, Inc. 156 625 0,82% SSgA Funds Management, Inc. 134 688 0,70%
Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions, such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs), and chronic low back pain (CLBP), associated with type I, or mixed type I and type II Modic changes (MCs). Its product candidate, AXS 05, is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions, such as treatment resistant depression (TRD), and agitation in patients with Alzheimer's disease (AD).
Rebound to $5 or higher coming ,stock is oversold and massive undervalued thanks to the onoing small share offering which created this fantastic entry opp . http://stockcharts.com/c-sc/sc?s=axsm&p=D&yr=0&mn=9&dy=0&i=p93834726544&r=3658
maybe the cheapest Nasdaq Biotech you can get with 5x Phase 3 in various indications and a laughable Market cap of $85 Million and $50 Million in cash .The fair value should be at $8-10 right now for this unknown Biotech . Latest stock market analyst ratings: Brean Capital began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 20 price target on the stock. Axsome Therapeutics, Inc. had its “” rating reiterated by analysts at Ladenburg Thalmann. They now have a USD 27 price target on the stock. Cantor Fitzgerald began new coverage on Axsome Therapeutics, Inc. giving the company a “” rating. They now have a USD 13 price target on the stock.
Hey guys if you own shares of this low float stock then please put a high GTC sell order in to prevent your shares from being borrowed to short . This will help to drive this brutally undervalued stock much higher .Thank You How to Prevent your Shares Holdings from being Shorted http://www.contracts-for-difference.com/Borrowing-lending-shares.html
Share offering is finished ..$5 or higher is still possible before Weekend Axsome Therapeutics Announces Full Exercise of Underwriter’s Option to Purchase Additional Shares .. https://globenewswire.com/news-rele...r-s-Option-to-Purchase-Additional-Shares.html
Good news could come on next Wednesday Axsome Therapeutics, Inc. at 16th Annual Needham Healthcare Conference (Live) April 5, 2017 at 8:40 a.m. ET
Looks like tree shaking ongoing to steal more cheap shares . AXSM is definitely one of the cheapest Nasdaq biotech i ever have seen before in last 18 years .GL Market cap: $84 million Cash: $50.6 Million NEW Presentation April http://phx.corporate-ir.net/Externa...9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1 Financial guidance: Recent financing extends estimated cash runway into the first quarter of 2019. AXS-05 Treatment Resistant Depression in Phase 3 -(Only 1 approved drug for TRD = unmet medical need. 3M patients in the U.S.) AXS-05 Agitation in Alzheimer’s Disease in Phase 2/3 -(No approved medication = unmet medical need. 2M patients in the U.S.) AXS-02 Complex Regional Pain Syndrome (CRPS) in Phase 3 (Orphan+Fast Track Status) -(No approved drug = high unmet need. 80,000 new cases per year in the U.S.) AXS-02 Knee Osteoarthritis (OA) with Bone Marrow Lesions (BMLs) in Phase 3 (SPA & Fast Track) -(7M patients in the U.S.) AXS-02 Chronic Low Back Pain(CLBP) with Modic Changes (MCs) in Phase 3 -(1.6M patients in the U.S.)
Very nice accumulation ongoing in last days ,this one will be over $10 before year end especially with positive phase 3 results next quarter .This is next ACAD in the making here
there we go guys we are over $4 ,, this stock is what i call a once in a lifetime opp this stock should be at $20 right now not at laughable $4 . 5 Phase 3 Programs two of them targeting very large Markets with NO approved Drugs . Marketcap: $90 Million Cash: $50 Million Price: $3.95 New Presentation http://phx.corporate-ir.net/Externa...9NjY0Mzk1fENoaWxkSUQ9MzcyMTk4fFR5cGU9MQ==&t=1 AXS-02 COAST-1 Knee Osteoarthritis Associated with Bone Marrow Lesions Phase 3 Phase 3 commenced March 2016. Interim analysis due 3Q 2017. AXS-02 CREATE-1 Complex regional pain syndrome (CRPS) Phase 3 Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017. AXS-02 Chronic Low Back Pain Associated with Modic Changes Phase 3 AXS-05 Agitation in patients with Alzheimer’s disease (AD) Phase 2/3 Phase 2/3 to be initiated 2Q 2017. AXS-05 STRIDE-1 Treatment resistant depression Phase 3 Phase 3 initiated March 2016. Top-line data due 1Q 2018.
New Investor bought a MASSIVE stake of 1.3 Million shares 5.5% , now the majority of the 22.9 million shares outstanding held by Insiders and Institutions which is a very good sign .GL 13g filing http://ih.advfn.com/p.php?pid=nmona&article=74443449
Fantastic News out today... Axsome Therapeutics Receives FDA Fast Track Designation for AXS-05 for Alzheimer’s Disease Agitation https://globenewswire.com/news-rele...AXS-05-for-Alzheimer-s-Disease-Agitation.html
Well written article out by J.Napodano Should You Invest In Axsome Therapeutics? Monday, May 8, 2017 http://www.talkmarkets.com/content/...you-invest-in-axsome-therapeutics?post=134346 Final Thoughts Axsome is very interesting to me. The company has four active Phase 3 clinical trials with two drug candidates. AXS-05 targets a host of mechanisms in the CNS that are clinically and commercially proven to be effective for the treatment of depression and agitation. The concept with AXS-05 is that dextromethorphan is pretty darn effective in treating depression, but has such poor bioavailability that it is hardly used. Bupropion synergistically improves the uptake of BM while providing baseline antidepressant effects. AXS-02 is an oral formulation of a well know bisphosphonate known to improve pain in CRPS and knee OA. I like the fact that Axsome has good insider ownership, plenty of cash, drugs with proven mechanisms of action, strong IP, and plenty of catalysts. Data from COAST-1 is expected in the Q3-2017. That's the first catalyst up for the company. CREATE-1 and STRIDE-1 are up in the Q4-2017 and Q1-2018, respectively. If the company goes 3-for-3, this stock will be north of $15.
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) May 10, 2017 https://www.networknewswire.com/net...y-rating-axsome-therapeutics-inc-nasdaq-axsm/ Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.
